IPSEN (OTCMKTS:IPSEY) Stock Short Interest Jumps 3,378.0%

IPSEN (OTCMKTS:IPSEY) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 1,426 shares, a growth of 3,378.0% from the September 15th total of 41 shares. Based on an average trading volume of 626 shares, the short-interest ratio is presently 2.3 days. Currently, 0.0% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

IPSEY has been the topic of a number of analyst reports. Jefferies Financial Group downgraded shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Finally, HC Wainwright restated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, IPSEN currently has a consensus rating of “Hold”.

IPSEN Price Performance

Shares of OTCMKTS IPSEY traded up $0.50 during mid-day trading on Friday, hitting $40.65. The company had a trading volume of 395 shares, compared to its average volume of 2,037. The stock’s 50-day moving average price is $45.32 and its 200-day moving average price is $46.31. IPSEN has a 1 year low of $32.68 and a 1 year high of $51.10.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in specialty care. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with an emphasis on treatments for conditions that often have limited therapeutic options.

The company’s portfolio includes Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected movement disorders and aesthetic applications, and cancer treatments such as Cabometyx and Onivyde.